Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%. Novo Nordisk said a Phase 1b/2a clinical trial of amycretin ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial. Shares were 10 ...

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed yesterday at $81.10. Nedelcovych covers the Healthcare ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk, which generates more than half of its sales in the United States. Novo, which competes with U.S ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...